Teladoc Health, Inc. (NYSE:TDOC) Position Boosted by Vigilare Wealth Management


Share on StockTwits

Vigilare Wealth Management raised its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,270 shares of the health services provider’s stock after acquiring an additional 50 shares during the quarter. Vigilare Wealth Management’s holdings in Teladoc Health were worth $254,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. grew its holdings in Teladoc Health by 1.7% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 2,778 shares of the health services provider’s stock valued at $609,000 after purchasing an additional 47 shares during the last quarter. Huntington National Bank lifted its stake in Teladoc Health by 11.3% in the fourth quarter. Huntington National Bank now owns 520 shares of the health services provider’s stock valued at $104,000 after buying an additional 53 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Teladoc Health by 2.5% in the third quarter. CIBC Asset Management Inc now owns 2,827 shares of the health services provider’s stock valued at $620,000 after buying an additional 70 shares during the last quarter. Tradewinds Capital Management LLC lifted its stake in Teladoc Health by 150.0% in the third quarter. Tradewinds Capital Management LLC now owns 125 shares of the health services provider’s stock valued at $27,000 after buying an additional 75 shares during the last quarter. Finally, Perigon Wealth Management LLC lifted its stake in Teladoc Health by 5.5% in the third quarter. Perigon Wealth Management LLC now owns 1,719 shares of the health services provider’s stock valued at $377,000 after buying an additional 89 shares during the last quarter. 87.39% of the stock is currently owned by institutional investors.

TDOC traded down $7.25 during trading on Thursday, reaching $224.54. The company had a trading volume of 76,638 shares, compared to its average volume of 3,182,888. The company has a debt-to-equity ratio of 0.73, a quick ratio of 11.36 and a current ratio of 11.36. Teladoc Health, Inc. has a 12-month low of $93.15 and a 12-month high of $253.00. The firm’s 50-day simple moving average is $203.08 and its 200 day simple moving average is $207.58. The company has a market cap of $32.55 billion, a price-to-earnings ratio of -181.09 and a beta of 0.25.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 28th. The health services provider reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.10). The business had revenue of $288.81 million for the quarter, compared to analysts’ expectations of $281.54 million. Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 9.54%. On average, sell-side analysts expect that Teladoc Health, Inc. will post -1.4 EPS for the current year.

A number of equities research analysts have issued reports on TDOC shares. Robert W. Baird upgraded Teladoc Health from a “neutral” rating to an “outperform” rating and set a $220.00 target price on the stock in a research note on Friday, November 13th. They noted that the move was a valuation call. Craig Hallum lifted their price objective on shares of Teladoc Health from $200.00 to $212.00 and gave the company a “hold” rating in a research note on Thursday, December 17th. Stephens cut shares of Teladoc Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $270.00 to $210.00 in a research note on Monday, December 7th. DA Davidson assumed coverage on shares of Teladoc Health in a research note on Tuesday, September 22nd. They set a “buy” rating and a $250.00 price objective on the stock. Finally, Canaccord Genuity lifted their price objective on shares of Teladoc Health from $255.00 to $261.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Thirteen research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Teladoc Health has an average rating of “Buy” and an average price target of $230.25.

In related news, SVP Andrew Turitz sold 1,389 shares of the company’s stock in a transaction dated Thursday, December 3rd. The shares were sold at an average price of $200.00, for a total transaction of $277,800.00. Following the completion of the sale, the senior vice president now owns 5,404 shares of the company’s stock, valued at approximately $1,080,800. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Adam C. Vandervoort sold 2,612 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $192.00, for a total transaction of $501,504.00. Following the sale, the insider now directly owns 1,647 shares of the company’s stock, valued at approximately $316,224. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,423 shares of company stock valued at $14,323,047. 3.42% of the stock is owned by corporate insiders.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.